← All drugs
Drug · FAERS side-effect profile with label screen

Clopidogrel side effects: what 197,000 FDA adverse event reports show

Clopidogrel · 1,220 reaction terms · 681,560 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Who reports

197,000 reports · 81% serious · 21,779 with death outcome · 44% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Clopidogrel tablets USP are a P2Y 12 platelet inhibitor indicated for: • Acute coronary syndrome • For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], clopidogrel tablets USP have been .

FDA label, Indications and Usage

What it is

Clopidogrel is a thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a methoxycarbonyl group (the S enantiomer).

PubChem CID 60606 (ChEBI)

Boxed warning

DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS The effectiveness of clopidogrel is dependent on its activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19 [ see Warnings and Precautions ( 5.1 ) ].

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled — boxed warning 2Labeled adverse reaction 2Labeled (related wording) 5Likely indication confounding 13Reporting / coding artifact 1Not in label — unassessed 17
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,180 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Vascular stent thrombosis64248.9
44.5–53.7ROR 49.1 · calibrated p 2e-5 ✓
33.6 EB05 31.4 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious n=642not reported in cached trials
Stent occlusion16747.6
39.6–57.2ROR 47.6 · calibrated p 2e-5 ✓
32.9 EB05 28.9 · IC025 +4.7
3/3 methods agree
Not in label — unassessedserious n=157 · 100% cliniciannot reported in cached trials
Coronary artery restenosis17342.7
35.8–51.0ROR 42.8 · calibrated p 4e-5 ✓
30.5 EB05 26.9 · IC025 +4.6
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=171 · ♀ 0% (drug 44%) · 100% cliniciannot reported in cached trials
Spinal epidural haematoma12329.5
24.1–36.0ROR 29.5 · calibrated p 3e-4 ✓
23.1 EB05 19.9 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=123 · ♀ 100% (drug 44%) · 100% cliniciannot reported in cached trials
Coronary arterial stent insertion93624.0
22.3–25.8ROR 24.1 · calibrated p 8e-4 ✓
19.7 EB05 18.6 · IC025 +4.2
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=926not reported in cached trials
Multiple injuries1,13022.8
21.4–24.3ROR 22.9 · calibrated p 0.001 ✓
18.9 EB05 17.9 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=1,129 · 85% consumernot reported in cached trials
Vascular pseudoaneurysm29121.1
18.6–24.0ROR 21.2 · calibrated p 0.002 ✓
17.7 EB05 16.1 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=286NCT00335452: 9/6,253 (0.1%) on Clopidogrel (serious AE)
Thrombosis in device54420.8
18.9–22.8ROR 20.8 · calibrated p 0.002 ✓
17.5 EB05 16.3 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=541not reported in cached trials
Labelled drug-drug interaction medication error1,32218.4
17.3–19.5ROR 18.5 · calibrated p 0.003 ✓
15.8 EB05 15.1 · IC025 +3.9
3/3 methods agree
Reporting / coding artifactserious PRR 13.1not reported in cached trials
Chronic kidney disease-mineral and bone disorder15017.1
14.4–20.3ROR 17.1 · calibrated p 0.004 ✓
14.8 EB05 12.9 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=150not reported in cached trials
Coronary artery stenosis70017.0
15.7–18.4ROR 17.1 · calibrated p 0.004 ✓
14.8 EB05 13.9 · IC025 +3.7
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=697not reported in cached trials
Haemorrhagic arteriovenous malformation12716.4
13.6–19.8ROR 16.4 · calibrated p 0.005 ✓
14.2 EB05 12.3 · IC025 +3.5
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=127 · ♀ 0% (drug 44%) · 100% consumernot reported in cached trials
Hyperparathyroidism secondary33616.2
14.4–18.1ROR 16.2 · calibrated p 0.005 ✓
14.1 EB05 12.9 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=336not reported in cached trials
Thrombotic thrombocytopenic purpura45615.7
14.2–17.3ROR 15.7 · calibrated p 0.006 ✓
13.7 EB05 12.7 · IC025 +3.6
3/3 methods agree
Labeled — boxed warning
exact term
serious n=456not reported in cached trials
Coronary artery thrombosis25815.4
13.5–17.6ROR 15.4 · calibrated p 0.006 ✓
13.5 EB05 12.2 · IC025 +3.5
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=255NCT00335452: 1/6,254 (0.0%) on Clopidogrel (serious AE)
Intermittent claudication20015.1
13.1–17.6ROR 15.2 · calibrated p 0.007 ✓
13.3 EB05 11.8 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=191not reported in cached trials
Angina unstable82015.1
14.0–16.2ROR 15.1 · calibrated p 0.007 ✓
13.3 EB05 12.5 · IC025 +3.6
3/3 methods agree
Likely indication confounding
term in indications
serious n=816not reported in cached trials
Nephrogenic anaemia57614.8
13.6–16.2ROR 14.9 · calibrated p 0.007 ✓
13.1 EB05 12.2 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=576NCT00335452: 2/6,253 (0.0%) on Clopidogrel (serious AE)
Angioplasty18414.8
12.7–17.3ROR 14.8 · calibrated p 0.008 ✓
13.0 EB05 11.5 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious n=182not reported in cached trials
Coronary artery occlusion1,65914.4
13.7–15.2ROR 14.6 · calibrated p 0.008 ✓
12.8 EB05 12.3 · IC025 +3.6
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious PRR 9.1not reported in cached trials
Carotid artery stenosis42114.4
13.0–15.9ROR 14.4 · calibrated p 0.008 ✓
12.7 EB05 11.7 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=419NCT00335452: 1/6,254 (0.0%) on Clopidogrel (serious AE)
Stent placement93813.9
13.0–14.9ROR 14.0 · calibrated p 0.009 ✓
12.4 EB05 11.7 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious PRR 8.8not reported in cached trials
Arterial haemorrhage13113.6
11.3–16.3ROR 13.6 · calibrated p 0.011 ✓
12.0 EB05 10.4 · IC025 +3.3
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=131 · ♀ 100% (drug 44%) · 100% clinicianNCT00335452: 1/6,254 (0.0%) on Clopidogrel (serious AE)
Ischaemic cardiomyopathy35013.4
12.0–15.0ROR 13.5 · calibrated p 0.011 ✓
12.0 EB05 11.0 · IC025 +3.4
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=348not reported in cached trials
Carotid arteriosclerosis11513.4
11.0–16.2ROR 13.4 · calibrated p 0.012 ✓
11.8 EB05 10.1 · IC025 +3.2
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=114 · ♀ 0% (drug 44%) · 100% cliniciannot reported in cached trials
Extradural haematoma14112.5
10.5–14.9ROR 12.5 · calibrated p 0.015 ✓
11.2 EB05 9.7 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=140 · 100% cliniciannot reported in cached trials
Acute myocardial infarction3,08312.3
11.8–12.7ROR 12.4 · calibrated p 0.015 ✓
11.1 EB05 10.8 · IC025 +3.4
3/3 methods agree
Likely indication confounding
term in indications
serious PRR 7.8NCT00335452: 1/6,254 (0.0%) on Clopidogrel (serious AE)
Retroperitoneal haemorrhage25312.0
10.6–13.7ROR 12.1 · calibrated p 0.017 ✓
10.8 EB05 9.7 · IC025 +3.2
3/3 methods agree
Labeled adverse reaction
exact term
serious n=253NCT00335452: 8/6,253 (0.1%) on Clopidogrel (serious AE)
Coronary artery disease3,08011.9
11.4–12.3ROR 12.0 · calibrated p 0.017 ✓
10.7 EB05 10.4 · IC025 +3.4
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious PRR 7.7not reported in cached trials
Peripheral arterial occlusive disease41311.8
10.7–13.1ROR 11.8 · calibrated p 0.018 ✓
10.7 EB05 9.8 · IC025 +3.2
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=407NCT00335452: 1/6,267 (0.0%) on Clopidogrel (serious AE)
Gastrointestinal haemorrhage8,28511.5
11.3–11.8ROR 12.0 · calibrated p 0.017 ✓
10.5 EB05 10.3 · IC025 +3.4
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 6.9 · serious PRR 7.5NCT00335452: 15/6,253 (0.2%) on Clopidogrel (serious AE)
Mallory-weiss syndrome12211.2
9.3–13.5ROR 11.2 · calibrated p 0.023 ✓
10.1 EB05 8.6 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious n=122 · ♀ 0% (drug 44%) · 100% cliniciannot reported in cached trials
Acute coronary syndrome77410.8
10.0–11.6ROR 10.8 · calibrated p 0.025 ✓
9.8 EB05 9.3 · IC025 +3.2
3/3 methods agree
Labeled — boxed warning
exact term
serious PRR 7.0NCT00335452: 1/6,267 (0.0%) on Clopidogrel (serious AE)
Peripheral artery occlusion12910.7
8.9–12.8ROR 10.7 · calibrated p 0.026 ✓
9.7 EB05 8.3 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious n=127 · 100% consumernot reported in cached trials
Melaena (black stool)1,99510.5
10.0–11.0ROR 10.6 · calibrated p 0.026 ✓
9.6 EB05 9.3 · IC025 +3.2
3/3 methods agree
Not in label — unassessedage-adj. PRR 6.3 · serious PRR 6.9NCT00335452: 1/6,312 (0.0%) on Clopidogrel (serious AE)

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Gi bleeding14,2458.98.8–9.1signal
Myocardial infarction12,4706.96.7–7.0signal
Stroke10,7464.84.7–4.8signal
Heart failure5,8733.63.5–3.7signal
Anaemia8,8923.23.2–3.3signal
Rhabdomyolysis / myopathy2,3183.13.0–3.2signal
Kidney injury11,8552.82.8–2.9signal
Arrhythmia / qt4,8242.72.6–2.8signal
Hyponatraemia1,9902.72.6–2.8signal
Hypoglycaemia2,0402.32.2–2.4signal
Fall / fracture7,1142.02.0–2.1raised
Hyperglycaemia / diabetes5,0691.61.5–1.6raised
Venous thromboembolism3,1121.51.5–1.6raised
Thrombocytopenia3,0231.51.4–1.5raised
Interstitial lung disease1,2741.41.3–1.5raised
Serious infection9,5361.31.3–1.3raised

Trial evidence (ClinicalTrials.gov)

✓ Trial adverse-event data found on ClinicalTrials.gov

Largest completed trials with posted results that list Clopidogrel as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (15 of 40 signal terms matched).

Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Dyspnoea (shortness of breath)10,1791.9
1.9–2.0ROR 2.0 · calibrated p 0.935
1.9 EB05 1.9 · IC025 +0.9Not in label — unassessedage-adj. PRR 1.6 · serious PRR 1.6NCT00335452: 2/6,312 (0.0%) on Clopidogrel (serious AE)
Myocardial infarction (heart attack)9,5316.0
5.9–6.2ROR 6.3 · calibrated p 0.132
5.8 EB05 5.7 · IC025 +2.5
3/3 methods agree
Likely indication confounding
term in indications
age-adj. PRR 5.5 · serious PRR 4.1NCT00335452: 1/6,254 (0.0%) on Clopidogrel (serious AE)
Fatigue (tiredness)8,7171.2
1.2–1.2ROR 1.2 · calibrated p 0.444
1.2 EB05 1.2 · IC025 +0.2Not in label — unassessedage-adj. PRR 1.0 · serious PRR 1.2NCT00335452: 1/6,312 (0.0%) on Clopidogrel (serious AE)
Gastrointestinal haemorrhage8,28511.5
11.3–11.8ROR 12.0 · calibrated p 0.017 ✓
10.5 EB05 10.3 · IC025 +3.4
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 6.9 · serious PRR 7.5NCT00335452: 15/6,253 (0.2%) on Clopidogrel (serious AE)
Nausea8,0811.1
1.1–1.1ROR 1.1 · calibrated p 0.369
1.1 EB05 1.1 · IC025 +0.1Not in label — unassessedage-adj. PRR 1.0 · serious PRR 1.1NCT00335452: 1/6,267 (0.0%) on Clopidogrel (serious AE)
Dizziness7,8841.7
1.7–1.7ROR 1.7 · calibrated p 0.785
1.7 EB05 1.7 · IC025 +0.7Not in label — unassessedage-adj. PRR 1.4 · serious PRR 1.6NCT00335452: 1/6,267 (0.0%) on Clopidogrel (serious AE)
Diarrhoea (diarrhea)7,6001.3
1.2–1.3ROR 1.3 · calibrated p 0.488
1.3 EB05 1.2 · IC025 +0.3Labeled adverse reaction
exact term
age-adj. PRR 1.0 · serious PRR 1.2NCT00335452: 1/6,253 (0.0%) on Clopidogrel (serious AE)
Drug ineffective (drug did not work)7,4050.6
0.6–0.6ROR 0.6 · calibrated p 0.077
0.6 EB05 0.6 · IC025 -0.8
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 0.7 · serious PRR 0.8not reported in cached trials
Asthenia (weakness)6,8592.0
1.9–2.0ROR 2.0 · calibrated p 0.941
1.9 EB05 1.9 · IC025 +0.9Not in label — unassessedage-adj. PRR 1.5 · serious PRR 1.6not reported in cached trials
Fall6,6972.2
2.1–2.2ROR 2.2 · calibrated p 0.947
2.1 EB05 2.1 · IC025 +1.1
3/3 methods agree
Not in label — unassessedage-adj. PRR 1.4 · serious PRR 1.7NCT00335452: 1/6,253 (0.0%) on Clopidogrel (serious AE)
Cerebrovascular accident (stroke)6,5234.2
4.1–4.3ROR 4.3 · calibrated p 0.323
4.1 EB05 4.0 · IC025 +2.0
3/3 methods agree
Labeled — boxed warning
synonym match
age-adj. PRR 3.4 · serious PRR 2.9not reported in cached trials
Death6,1800.8
0.7–0.8ROR 0.8 · calibrated p 0.158
0.8 EB05 0.7 · IC025 -0.4
PRR-only: not supported by EBGM or IC
Outcome field, not a reactionage-adj. PRR 0.5 · serious PRR 0.5not reported in cached trials
Anaemia (low red blood cells)6,1553.5
3.4–3.6ROR 3.6 · calibrated p 0.462
3.4 EB05 3.4 · IC025 +1.7
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.8 · serious PRR 2.6NCT00335452: 2/6,312 (0.0%) on Clopidogrel (serious AE)
Headache5,6051.0
0.9–1.0ROR 1.0 · calibrated p 0.275
1.0 EB05 0.9 · IC025 -0.1
PRR-only: not supported by EBGM or IC
Labeled adverse reaction
exact term
age-adj. PRR 1.0 · serious PRR 1.0NCT00335452: 1/6,254 (0.0%) on Clopidogrel (serious AE)
Pain5,5171.0
0.9–1.0ROR 1.0 · calibrated p 0.276
1.0 EB05 0.9 · IC025 -0.1
PRR-only: not supported by EBGM or IC
Not in label — unassessedage-adj. PRR 1.1 · serious PRR 0.9NCT00335452: 3/6,253 (0.0%) on Clopidogrel (serious AE)

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Clopidogrel ↔ Gastrointestinal haemorrhage.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Clopidogrel?

In FDA FAERS, the most frequently co-reported reaction terms for Clopidogrel are dyspnoea, myocardial infarction, fatigue, gastrointestinal haemorrhage, nausea, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Clopidogrel have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS The effectiveness of clopidogrel is dependent on its activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19 [ see Warnings and Precautions ( 5.1 ) ].

Do FAERS signals prove that Clopidogrel causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.